BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36356632)

  • 1. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
    Schlaich MP; Bellet M; Weber MA; Danaietash P; Bakris GL; Flack JM; Dreier RF; Sassi-Sayadi M; Haskell LP; Narkiewicz K; Wang JG;
    Lancet; 2022 Dec; 400(10367):1927-1937. PubMed ID: 36356632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.
    Verweij P; Danaietash P; Flamion B; Ménard J; Bellet M
    Hypertension; 2020 Apr; 75(4):956-965. PubMed ID: 32063059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
    Danaietash P; Verweij P; Wang JG; Dresser G; Kantola I; Lawrence MK; Narkiewicz K; Schlaich M; Bellet M;
    J Clin Hypertens (Greenwich); 2022 Jul; 24(7):804-813. PubMed ID: 35686330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.
    Weber MA; Black H; Bakris G; Krum H; Linas S; Weiss R; Linseman JV; Wiens BL; Warren MS; Lindholm LH
    Lancet; 2009 Oct; 374(9699):1423-31. PubMed ID: 19748665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
    Chow CK; Atkins ER; Hillis GS; Nelson MR; Reid CM; Schlaich MP; Hay P; Rogers K; Billot L; Burke M; Chalmers J; Neal B; Patel A; Usherwood T; Webster R; Rodgers A;
    Lancet; 2021 Sep; 398(10305):1043-1052. PubMed ID: 34469767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
    Williams B; MacDonald TM; Morant S; Webb DJ; Sever P; McInnes G; Ford I; Cruickshank JK; Caulfield MJ; Salsbury J; Mackenzie I; Padmanabhan S; Brown MJ;
    Lancet; 2015 Nov; 386(10008):2059-2068. PubMed ID: 26414968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
    Chow CK; Thakkar J; Bennett A; Hillis G; Burke M; Usherwood T; Vo K; Rogers K; Atkins E; Webster R; Chou M; Dehbi HM; Salam A; Patel A; Neal B; Peiris D; Krum H; Chalmers J; Nelson M; Reid CM; Woodward M; Hilmer S; Thom S; Rodgers A
    Lancet; 2017 Mar; 389(10073):1035-1042. PubMed ID: 28190578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
    Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M;
    Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
    Kandzari DE; Böhm M; Mahfoud F; Townsend RR; Weber MA; Pocock S; Tsioufis K; Tousoulis D; Choi JW; East C; Brar S; Cohen SA; Fahy M; Pilcher G; Kario K;
    Lancet; 2018 Jun; 391(10137):2346-2355. PubMed ID: 29803589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
    Azizi M; Sanghvi K; Saxena M; Gosse P; Reilly JP; Levy T; Rump LC; Persu A; Basile J; Bloch MJ; Daemen J; Lobo MD; Mahfoud F; Schmieder RE; Sharp ASP; Weber MA; Sapoval M; Fong P; Pathak A; Lantelme P; Hsi D; Bangalore S; Witkowski A; Weil J; Kably B; Barman NC; Reeve-Stoffer H; Coleman L; McClure CK; Kirtane AJ;
    Lancet; 2021 Jun; 397(10293):2476-2486. PubMed ID: 34010611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F; Kandzari DE; Kario K; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Dimitriadis K; Choi JW; East C; D'Souza R; Sharp ASP; Ewen S; Walton A; Hopper I; Brar S; McKenna P; Fahy M; Böhm M
    Lancet; 2022 Apr; 399(10333):1401-1410. PubMed ID: 35390320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.
    Azizi M; Sapoval M; Gosse P; Monge M; Bobrie G; Delsart P; Midulla M; Mounier-Véhier C; Courand PY; Lantelme P; Denolle T; Dourmap-Collas C; Trillaud H; Pereira H; Plouin PF; Chatellier G;
    Lancet; 2015 May; 385(9981):1957-65. PubMed ID: 25631070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study.
    Payeras AC; Sladek K; Lembo G; Alberici M
    Clin Drug Investig; 2007; 27(9):623-32. PubMed ID: 17705571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension.
    Heidari Nejad S; Azzam O; Schlaich MP
    Curr Hypertens Rep; 2023 Oct; 25(10):343-352. PubMed ID: 37566184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.
    Parvanova A; van der Meer IM; Iliev I; Perna A; Gaspari F; Trevisan R; Bossi A; Remuzzi G; Benigni A; Ruggenenti P;
    Lancet Diabetes Endocrinol; 2013 Sep; 1(1):19-27. PubMed ID: 24622263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    McGill JB; Reilly PA
    Clin Ther; 2001 Jun; 23(6):833-50. PubMed ID: 11440284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
    Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
    Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.